2019

Retinoic acid receptors in acute myeloid leukemia therapy

Orsola di Martino
John S Welch

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Abstract: Retinoic acid (RA) signaling pathways regulate fundamental biological processes, such as cell proliferation, development, differentiation, and apoptosis. Retinoid receptors (RARs and RXRs) are ligand-dependent transcription factors. All-trans retinoic acid (ATRA) is the principal endogenous ligand for the retinoic acid receptor alpha (RARA) and is produced by the enzymatic oxidation of dietary vitamin A, whose deficiency is associated with several pathological conditions. Differentiation therapy using ATRA revolutionized the outcome of acute promyelocytic leukemia (APL), although attempts to replicate these results in other cancer types have been met with more modest results. A better knowledge of RA signaling in different leukemia contexts is required to improve initial designs. Here, we will review the RA signaling pathway in normal and malignant hematopoiesis, and will discuss the advantages and the limitations related to retinoid therapy in acute myeloid leukemia.

Keywords: retinoid therapy; APL; AML; ATRA

1. Introduction

Nuclear receptors (NRs) are ligand-dependent transcription factors that bind DNA sequence-specific motifs in enhancers and promoters to transactivate their target genes [1]. The NR superfamily is characterized by a highly conserved structure consisting of a DNA-binding domain (DBD), a ligand-binding domain (LBD), and N and C-terminal transactivation domains. NRs can act as monomers, homodimers, or heterodimers [1–3]. The retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are ligand-activated NRs that have pleiotropic effects including the control of hematopoietic stem cell self-renewal and differentiation [4–6]. There are three different isoforms of each receptor (α, β, and γ) that are differently expressed in mouse and human tissues [7,8].

Retinoid receptors are activated by retinoids, small molecules derived from dietary vitamin A. Vitamin A is a fat-soluble compound derived from beta-carotene found in plants and retinyl esters from animal sources. Following ingestion, vitamin A is stored in the liver and adipose tissue as retinyl esters and circulates in the blood in a protein complex containing retinol-binding protein and transthyretin [4,9]. Retinyl esters are reversibly oxidized to retinal by retinol dehydrogenase enzymes (ADHs) [10]. Retinal is irreversibly oxidized to all-trans retinoic acid (ATRA) by aldehyde dehydrogenases (ALDHs) [10,11]. In humans, 19 different ALDHs have been identified. Only a small proportion of circulating retinol is converted to ATRA (0.2–5%), and ATRA is subsequently further metabolized to inactive forms by cytochrome P450 enzymes (mainly CYP26 family) [12]. ATRA is considered the principal ligand for the retinoic acid receptor alpha (RARA) [13].

Retinoic acid (RA) signaling pathways regulate essential biological functions, such as cell development, differentiation, proliferation, and apoptosis, and the expression of retinoid receptors is downregulated in several tumor types [4,10,14,15]. RA signaling is crucial for mammalian
post-implantation development and organogenesis, and vitamin A deficiency is associated with embryo and fetal malformation [15,16]. The availability of RA modulates the expression of genes involved in differentiation, and the RA gradient distribution thereby tunes the patterning of hematopoietic, hepatic, and neural stem/progenitor cell populations [4,6,16,17]. In the adult, RA signaling remains relevant in hematopoietic stem cells, where RARG activity plays a critical role in maintaining the stem cell pool [17,18].

RARs function as obligate heterodimers with RXRs. Ligand binding induces structural changes that alter the transcriptional activity of the heterodimer. In the absence of ligands, RAR-RXR acts as a transcriptional repressor by binding co-repressor complexes and recruiting histone deacetylases (HDACs) [19,20]. Ligand binding alters the position of helix 12, displacing the co-repressors and facilitating binding of co-activator complexes with histone acetylase activity (HATs).

Retinoids have found a clinical role in the treatment of acute promyelocytic leukemia (APL) (M3 subtype of acute myeloid leukemia), which is associated with translocations involving RARA and which undergo maturation in response to ATRA [21,22]. APL is characterized by the pathognomonic presence of the fusion protein PML/RARA, which acts as a transcriptional repressor impairing the expression of genes that are critical to myeloid differentiation [23–25]. Retinoid therapy transformed response and survival outcomes of APL. Lo Coco et al. demonstrated that a combination of ATRA and arsenic trioxide (ATO) leads to complete remission (97% two-year event-free survival rates in the ATRA/ATO treated patients and p < 0.001) [25]. However, differentiation therapy with ATRA in non-APL acute myeloid leukemia (AML) has yielded mixed results, suggesting that subgroups of patients may possess greater or lesser retinoid sensitivity [26]. In particular, AML with nucleophosmin (NPM1) mutations [27,28], EVI-1 expression [29], and IDH2 mutations [30] have been suggested to possess greater ATRA sensitivity. Additional studies examined the sensitivity to the RXR-selective ligand bexarotene, which also induces maturation and apoptosis in some AML cell lines and primary AML patient samples [31–33], suggesting a potential clinical role for other retinoids in cancer therapy.

2. Retinoid Acid Receptors: Structure and Mechanism of Action

RARs and RXRs have a conserved modular structure with an N-terminal ligand-independent activation function (AF-1), a central conserved DNA-binding domain (DBD), and a C-terminal ligand-binding domain (LBD) [34,35]. The multifunctional LBD is responsible for ligand binding and dimerization and contains a ligand-dependent activation function (AF-2), which corresponds to coregulator interaction surfaces that can be modulated by natural (e.g., retinoic acid) or pharmacological ligands (e.g., tamibarotene and bexarotene) [20,36,37]. RARs function as obligate heterodimers with RXRs, whereas RXR is a promiscuous heterodimerization partner with different nuclear receptors (e.g., peroxisome proliferator-activated receptors (PPARs), liver X receptor (LXRs), nuclear bile receptor (FXR), the thyroid hormone receptor (TR), and the vitamin D receptor (VDR)) [1].

The transcriptional activity of the retinoic acid receptor (RAR)-retinoid X receptor (RXR) heterodimer is regulated by the absence/presence of a binding ligand that generates conformational changes modulating the RAR-RXR complex [1,38,39]. In general, RAR-RXR dimers bind DNA with high affinity at specific retinoic acid response elements (RAREs) in target gene promoters/enhancers [19,40]. In the absence of a ligand (or in the presence of an antagonist), local transcriptional activity is repressed through the recruitment of the corepressor complexes (CoRs) in the promoter region of target genes [19,20]. The most common corepressors to interact with RAR/RXR heterodimers are the nuclear receptor corepressor (N-CoR) [41] and the silencing mediator for retinoid and thyroid hormone receptors (SMRT) [42], which are each capable of further recruiting histone deacetylases (HDACs) [40,43,44]. Local histone deacetylation then facilitates chromatin condensation and gene silencing [40]. In contrast, when an active ligand binds, this induces a structural shift in the C-terminal region of the LBD, helix H12, leading to destabilization of the CoR-binding and subsequent coactivator (CoAs) recruitment. The structural crosstalk between the RAR and RXR H12 regions is crucial for RAR regulation. Once bound,
the CoA p160 family (TIF-2/SRC-1/RAC3) recruits histone acetyltransferase complexes (HATs) [45–47], which facilitate chromatin de-condensation and gene transcription activation.

The corepressor N-CoR contains evolutionarily conserved structured regions involved in transient intramolecular contacts. In the presence of RXR/RAR, N-CoR exploits its multi-valency to form a cooperative multisite complex that displays an equilibrium between different conformational states. Structural analysis of the RAR/RXR heterodimer revealed that in the absence of a ligand, the H12 helices are inclined to an extended helical position, whereas the presence of a specific ligand or receptor mutation results in re-orientation of this helix. This equilibrium is crucial to maintaining the repressive basal state while allows for the conversion to a transcriptionally active form [20]. A negative feedback mechanism controls RARA levels—upon ligand binding, RARA is ubiquitinated and degraded via the proteasome [14].

Different RXR heterodimers display different responsiveness to activation of individual elements in the diad. Some heterodimers function “permissively”, being capable of responding when the ligand binds either element of the heterodimer (e.g., PPAR/RXR, LXR/RXR, FXR/RXR) or “non-permissively”, being only capable of responding to ligands bound to the non-RXR element in the heterodimer (e.g., RAR/RXR, VDR/RXR and TR/RXR) heterodimers [1,48–50]. Steric interactions between the conformations of the two helices, 12 domains appear critical to modulate these phenotypes.

2.1. Retinoid Acid Signaling Pathway

RA signaling controls the transcriptional activity of genes involved in cell growth, differentiation, and apoptosis in normal and cancer tissues. RARs and RXRs are expressed at early developmental stages in vertebrate embryos of various species, and RA signaling is fundamental for the maintenance of homeostatic control during embryonic and fetal development [17,51]. All-trans retinoic acid (ATRA) is the principal activator of RA signaling through binding to RARA receptors [52]. Upon uptake, Vitamin A is stored in the liver as retinyl esters [4]. In the plasma, retinyl acetate and retinol are largely protein-bound and can be found at micromolar concentrations [4]. Intracellular transport is regulated by retinol transporters such as STRA6 [53]. Once intracellular, retinol is oxidized by retinol dehydrogenase (RDH/ADH) to retinal, and then retinal is irreversibly oxidized to ATRA via retinal dehydrogenases (ALDH1A1, ALDH1A2, ALDH1A3, and Aldh3b1) [52,54]. The physiological levels of ATRA are further regulated through ATRA metabolism by cytochrome P450 enzymes (mainly, CYP26 family) [52].

ATRA is a highly potent agonist of all three RARs, with low nM EC50. In contrast, ATRA activates RXRs at near micromolar concentrations [4]. Further metabolism leads to active isomers such as 9-cis retinoic acid and 13-cis retinoic acid [4]. 9-cis retinoic acid has been identified as a potent RXR agonist, although the physiological relevance of this molecule in vivo remains controversial [55]. 13-cis retinoic acid is a less potent RARA ligand than ATRA [56,57].

Alternative, non-retinoic acid compounds have emerged as potential natural RXR ligands, specifically, long-chain fatty acids (e.g., docosahexaenoic acid (DHA) and C24:5) have been shown to be low-affinity RXR endogenous agonists and appear to be present in vivo at physiologically relevant concentrations [57,58].

2.1.1. Vitamin A Deficient (VAD) Mice

RA signaling is essential for hematopoietic and immune system development, function, and homeostasis. In normal hematopoiesis, RARA and RXRA are dynamically regulated during myeloid maturation, with the highest expression in mature neutrophils (Figure 1) [41]. The function of natural retinoids has been explored by characterizing hematopoietic and immune phenotypes in Vitamin A deficient (VAD) mice. VAD mice display an abnormal expansion of myeloid cells (mainly terminally differentiating granulocytes expressing the Mac-1 and Gr-1 surface antigen) in bone marrow, spleen, and peripheral blood that can be reversed upon ATRA administration [59], whereas RARA dominant-negative mutations and RARA antagonists (i.e., BMS493 Pan-RAR inverse agonist) block
myeloid maturation, leading to increased numbers of myeloid precursors [27,60,61]. Adult mice fed with a Vitamin A free diet for 14–17 weeks showed a reduction in bone marrow cellularity and a decrease of hematopoietic stem cells frequency and plasticity [18].

Figure 1. Expression profile of retinoic acid receptor alpha (RARA) and retinoic X receptor alpha (RXRA) in human samples. Expression profile of retinoid receptors in total bone marrow cells from 197 human AML cases and sorted normal bone marrow cells using RNA Seq. FAB is indicated on X-axis. (https://leylab.shinyapps.io/TCGA_AML_Web_App/).

Although RARA and RXRA are expressed at lower levels in bone marrow B and T cells compared with neutrophils (Figure 1), VAD mice displayed compromised T and B cell immune-response phenotypes [59,60]. In B cells, VAD mice displayed altered proliferation and differentiation with a reduction of IgA isotype switching and reduced generation of antibody-secreting plasma cells [61,62]. VAD mice also showed an altered lymph node development with decreased T cell differentiation and reduced migration into tissues [61–63].

2.1.2. Rars and Rxrs Knockout Mice

The contribution of each RAR and RXR isoform to hematopoiesis has been explored through the generation of knockout mice. During development, Rara is widely expressed, whereas Rarb and Rarg display tissue-specific expression patterns [64]. Rara, Rarb, and Rarg single knockout mice largely maintain normal hematopoiesis, suggesting that the different isoforms can play compensatory roles. The exception is Rarg knockout mice, which display a decreased number of hematopoietic stem cells (HSCs) and more mature progenitors [51]. Rara/Rarg double knockout mice show early lethality due to several embryonic malformations [6,65]. Fetal liver cells of Rara/Rarg double knockout mice are composed mainly of mature granulocytes similar to wild-type mice with no increase of Rarb expression level, suggesting that expression of Rarb is not modulated by the retinoid receptor feedback mechanisms [6].

RXRs are also expressed differentially in mouse tissues. Rxra and Rxrb have wide expression, whereas Rxrg is expressed in skeletal muscle and CNS, with limited (if any) expression in hematopoietic cells [39]. RXRs have been implicated in hematopoietic cell fate. RXRA downregulation is required for neutrophil terminal differentiation from human myeloid progenitors [39,66]. However, Rxra and Rxrb single knockout mice do not display gross defects related to hematopoiesis, supporting a compensatory role of these RXR isoforms [66,67]. Rxra/Rxrb double knockout mice show early developmental lethality due to the lack of formation of the labyrinthine zone of the chorioallantoic placenta [68].

2.2. Retinoid Acid Signaling Pathway in Cancer and Leukemia

RA signaling alteration has been implicated in the oncogenesis of diverse cancer types. Retinoic acid signaling has been implicated both as a tumor suppressor and an oncogene in a context-dependent manner. Enzymes involved in the chemical conversion of Vitamin A to ATRA are frequently
down-regulated during oncogenesis [14]. Retinol acetyl-transferase downregulation has been associated with breast and skin carcinogenesis [10]. Cellular retinol binding protein 1 (CRBP1) is inactivated by gene-hypermethylation in human breast cancer [15, 69], whereas the enzyme CYP26A1, that degrades the ATRA, is overexpressed [70, 71]. Retinaldehyde dehydrogenase 1 (ALDH1) is a functional marker commonly used to identify cancer stem cells and its expression is associated with poor prognosis in several cancer types [72]. In prostate cancer, retinaldehyde dehydrogenase 2 (ALDH1A2) is silenced by locus hypermethylation and acts as a tumor suppressor [64, 73]. Retinoic acid receptor beta 2 (RARβ2) has been shown to have tumor suppressor activity in a series of human carcinomas (e.g., breast and prostate cancer) [74, 75]. However, inactivation of stromal Rarb in the mouse results in a protective effect against ErbB2-induced mammary gland tumorigenesis [76], suggesting pleiotropic and tissue-specific effects. In a mouse model of chronic lymphocytic leukemia (CLL), characterized by the abnormal expansion of CD5+ B-cells in bone marrow and secondary lymphoid organs, there is increased RA signaling activity by leukemic cells with accumulation of ATRA in the stromal microenvironment as result. The inhibition of RA signaling with the pan-RARA inverse agonist, BMS493, reduced the leukemia burden of CLL cells in vitro and in vivo [77].

Recent RXRA mutations are found in 5–8% of human bladder cancer [78]. Mutant RXRA protein results in increased binding to the peroxisome proliferator activator receptor (PPAR) and hyperactivation of PPAR target genes that support tumor growth, raising the potential for therapeutic intervention targeting the PPARG-RXRA heterodimer [79].

Retinoic acid receptor (RAR) and retinoid X receptor (RXR) are nuclear receptors that belong to the superfamily of ligand-activated receptors. They are involved in gene transcription and play a key role in development, differentiation, and cancer. The RARs are activated by retinoic acid (RA), a product of retinol metabolism. RXR acts as a transcriptional coactivator and is essential for the activation of genes regulated by RARs. The RXR-RAR heterodimer regulates the expression of genes involved in cell proliferation, differentiation, and apoptosis, and is implicated in various diseases, including cancer.

Regulation of HAT and HDAC enzymes is crucial for gene transcription. HATs are among the most frequently mutated genes in urothelial carcinomas and upregulation of HDACs has been noted in a wide variety of cancers [83, 84]. In particular, several HDACs have been found to be upregulated in acute lymphoblastic leukemia (ALL) and are associated with a poor prognosis. 5-azacytidine and 5-aza-2′-deoxycytidine (decitabine, DAC), a DNMT inhibitor, are used in the treatment of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with myelodysplastic syndromes (MDS) and AML [85]. Combinations of decitabine and HDAC inhibitors appeared logical, with pre-clinical synergistic effects on gene expression re-activation [86], but resulted in limited clinical efficacy in clinical trials [87].

2.2.1. Retinoid Therapy in Acute Promyelocytic Leukemia

Acute Myeloid leukemia (AML) is the most frequent form of leukemia among adults, characterized by an uncontrolled accumulation of myeloid precursor cells. Ninety-five percent of acute promyelocytic leukemia cases are associated with the t(15;17)(q22;q11) chromosomal translocation, which results in the fusion of the promyelocytic leukemia gene (PML) and the RARA gene, generating the fusion protein “PML-RARA” [24, 25]. Additional RARA fusion partners have also been described, although these occur with less frequency—the promyelocytic leukemia zinc finger (PLZF), nuclear mitotic apparatus (NUMA), and the signal transducer and activator of transcription 5b (STAT5B) or nucleophosmin 1 (NPM1) are the most common of these alternative partners [88]. Rare cases of RARG fusions have also been described with promyelocytic morphology [89]. The balanced translocation of t(15;17);t(17;15) is associated with the expression of a reciprocal fusion product (RARA-PML), and is accompanied by haploinsufficiency for both PML and RARA [90, 91]. PML-RARA binds the HDAC complex with higher affinity than the RARA-RXR heterodimer, causing a block of differentiation at the promyelocytic stage.
due to gene transcription repression [92]. PML-RARA forms homodimers and can heterodimerize with wild type PML and RXR, inhibiting their functions.

APL is an aggressive form of AML, however, combination therapy with ATRA and arsenic trioxide (ATO) is highly effective [25,93]. Pharmacologic doses of ATRA induce the displacement of the HDAC complex from the fusion protein PML-RARA and unlock the terminal differentiation of APL blasts to granulocytes (Figure 2). ATRA binding leads to subsequent PML-RARA degradation [94]. In parallel, ATO binds to PML, leading to its degradation in parallel with APL blast differentiation and apoptosis [25,95].

Figure 2. Differentiation therapy in APL. (A) In APL blast cells the fusion protein PML-RARA forms oligodimers and binds the DNA with higher affinity than the wild type RARA. The binding of PML-RARA to RARA sequence allows the co-repressor (CoR)-HDAC complex recruitment leading to gene expression repression. (B) Administration of pharmacological doses of ATRA leads to CoR-HDAC release and recruitment of the co-activator (CoA)-HAT complex that activates gene expression.

2.2.2. Resistance to Differentiation Therapy in APL Patients

A recurrent cause of acquired clinical resistance to ATRA treatment in APL patients is the acquisition of missense mutations (e.g., Leu290Val, Arg394Trp, and Met413Thr) in the RARA-LBD of the fusion protein, PML-RARA [14]. This form of resistance emerges most commonly at the second relapse, and in patients treated with low-dose consolidation or maintenance chemotherapy [96]. Non-PML-RARA translocations tend to be resistant to ATRA/ATO. PLFZ-RARA is able to bind and transactivate its target gene with higher affinity than PML-RARA. A second resistance mechanism involves overexpression of cellular retinoic acid-binding protein (CRABP1), which may reduce intracellular free ATRA availability [97]. PLFZ is a transcription factor and can regulate the recruitment of CoA even in the presence of pharmacological concentrations of ATRA. The molecular mechanisms underlying ATRA-resistance in STAT5b-RARA patients are not fully understood. One of the reasons could be related to the presence of STAT5b-RARA in the nucleus (Stat5b is localized in cytoplasm) with
subsequent aberrant expression of both RARA and STAT5b target genes. Neither PLZF-RARA nor STAT5b-PML patients appear sensitive to ATO, likely because ATO effects occur through its binding to PML [98,99].

The synthetic retinoid tamibarotene (Am80) has been tested in APL patients to overcome ATRA resistance in high-risk patients. Tamibarotene is ten times more potent than ATRA, has binding specificity for RARA, and has low affinity for CRABP1 [97]. In addition, it is more stable to light, heat and oxidation than ATRA, and its plasma levels do not decline after daily administration [100]. Tamibarotene was approved in Japan in 2004 for APL treatment but is not available in the United States. Results from a Japanese clinical trial (JALSG-APL204) with a median follow-up of 7.3 years showed the relapse-free survival (RFS) at 7 years was 93% in the tamibarotene arm and 84% in the ATRA arm ($p = 0.027, \text{ HR = 0.44, 95\% CI, 0.21 to 0.93}$) [101].

2.2.3. Retinoid Acid Signaling Pathway as a Potential Target for Acute Myeloid Leukemia Therapy

Differentiation therapy with ATRA in non-APL AML has yielded mixed results [26]. Therefore, subgroups have been sought to identify patients with enhanced retinoid sensitivity. AML is associated with altered expression of chromatin modifying genes, such as the histone deacetylase HDACs, the DNA methyltransferase DMNTs, and the mono- and di-methyl lysine demethylase LSD1 (KDM1A) [102]. Cases with high LSD1 expression have been associated with epigenetic suppression of RARα2 expression [102,103]. Consistent with this, treatment with the LSD1 inhibitor, trans-2-phenylcyclopropylamine (TCP), augmented retinoic acid differentiation and ATRA-sensitivity in ATRA responsive and non-responsive AML cell lines [104].

Super-enhancer analysis in primary AML samples identified a sub-group of AML patients with a super-enhancer in the RARA locus, which are highly responsive to SY-1425, a potent and selective RARA agonist [105].

Patients with NPM1 mutations may also be preferentially sensitive to ATRA or to combinations of ATRA and ATO. Subgroup analysis suggested that the addition of ATRA to chemotherapy was associated with improved responses in NPM1 mutated-AML patients. These results were supported by the in vitro sensitivity of NPM1 mutated-AML cells treated with ATRA/ATO, which induced proteasome-mediated apoptosis [27,28,106].

AML with IDH2 mutations have been associated with LSD1 de-regulation and a transcriptional signature of ATRA sensitization. Consistent with this, the ATRA/arsenic trioxide combination led to responses in model systems with phenotypes suggestive of the differentiation syndrome [30]. Finally, EVI-1 enhanced expression occurred in almost 10% of AML patients and is correlated with poor outcomes (overall survival of <1 year). Intriguingly, ATRA treatment lead to blasts differentiation and reduction in leukemic engraftment in a subset of patients-derived primary human AML cells with ecotropic viral integration site 1 (EVI-1) overexpression [29,107].

Finally, ATRA may serve as a chemosensitizer. ATRA increases the expression of CD38, a transmembrane glycoprotein expressed on hematopoietic cells and the target of Daratumumab. Pre-clinical data suggests this combination augments leukemia cell death [108].

2.2.4. Role of Autophagy in Acute Myeloid Leukemia Retinoid Therapy

Autophagy is a key mechanism that maintains cellular metabolism and homeostasis through degradation of intracellular components, such as organelles and damaged or redundant proteins [109]. The autophagosome is a bi-membrane vesicle that envelopes the cellular content targeted for degradation. This highly conserved mechanism protects cells from metabolic/environmental stress (e.g., nutrient deprivation, hypoxia, and chemotherapies) and controls cell self-renewal, differentiation, and death [110]. Autophagy is crucial for the maintenance of HSCs. Autophagy gene expression levels are downregulated in APL cells resulting in a low autophagy activity, which may cooperate with PML-RARA to lead to the development of leukemia [111]. It has been shown that ATRA administration...
can stimulate autophagosomes accumulation and induce degradation in APL and non-APL cell lines by stimulating granulocytes differentiation [112].

2.2.5. Rexinoids in Acute Myeloid Leukemia Therapy

Rexinoids are a class of potent synthetic specific RXR ligands, which have been explored in AML [39,113,114]. Bexarotene is a pan-RXR ligand that is approved by Food and Drug Administration agency in the United States for the treatment of cutaneous T-cell lymphoma (CTCL) and has been tested for other cancer types [113]. Several studies have been conducted to show the efficacy of bexarotene in AML. An initial study of relapsed or refractory AML treated with bexarotene as monotherapy results in the induction of myeloid differentiation in two patients [115]. Differentiation induced by bexarotene was also noted in AML cell lines, and the pro-differentiative effect could be enhanced by the combination with the LXR agonist T0901317 [33]. A second clinical trial combined increased bexarotene doses with decitabine (DNA hypomethylation agent) in older and relapsed AML patients. This combination was well tolerated in patients but also resulted in only modest responses [116].

3. Conclusions

Natural and synthetic derived retinoids are a class of compounds commonly used as therapeutic agents in oncology. Retinoids have been explored in diverse cancer types, including lung cancer, breast cancer, and AML, and are FDA approved to treat APL and cutaneous T cell lymphoma. In the case of APL, the combination of ATRA and ATO has resulted in striking efficacy and long term survival. Retinoid treatments in other leukemia subtypes have resulted in mixed outcomes, although emerging biomarkers suggest that subgroups may exist with enhanced sensitivity. Further understanding of the co-activator/co-repressor interactions with the retinoid receptors may enable broader application of retinoids in diverse cancer types.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Evans, R.M.; Mangelsdorf, D.J. Nuclear Receptors, RXR, and the Big Bang. Cell 2014, 157, 255–266. [CrossRef]
2. Baniahmad, A.; Thorneyer, D.; Renkawitz, R. tau4/tau c/AF-2 of the thyroid hormone receptor relieves silencing of the retinoic acid receptor silencer core independent of both tau4 activation function and full dissociation of corepressors. Mol. Cell. Biol. 1997, 17, 4259–4271. [CrossRef] [PubMed]
3. Martin, N.; Ma, X.; Bernard, D. Regulation of cellular senescence by retinoid X receptors and their partners. Mech. Ageing Dev. 2019, 183, 111131. [CrossRef] [PubMed]
4. Bushue, N.; Wan, Y.J. Retinoid pathway and cancer therapeutics. Adv. Drug Deliv. Rev. 2010, 62, 1285–1298. [CrossRef] [PubMed]
5. Oren, T.; Sher, J.A.; Evans, T. Hematopoiesis and retinoids: Development and disease. Leuk. Lymphoma 2003, 44, 1881–1891. [CrossRef] [PubMed]
6. Kastner, P.; Chan, S. Function of RARalpha during the maturation of neutrophils. Oncogene 2001, 20, 7178–7185. [CrossRef]
7. Purton, L.E.; Dworkin, S.; Olsen, G.H.; Walkley, C.R.; Fabb, S.A.; Collins, S.J.; Chambon, P. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J. Exp. Med. 2006, 203, 1283–1293. [CrossRef]
8. Lefebvre, P.; Benomar, Y.; Staels, B. Retinoid X receptors: Common heterodimerization partners with distinct functions. Trends Endocrinol. Metab. 2010, 21, 676–683. [CrossRef]
9. O’Byrne, S.M.; Blaner, W.S. Retinol and retinyl esters: Biochemistry and physiology. J. Lipid Res. 2013, 54, 1731–1743. [CrossRef]
10. Guo, X.; Ruiz, A.; Rando, R.R.; Bok, D.; Gudas, L.J. Esterification of all-trans-retinol in normal human epithelial cell strains and carcinoma lines from oral cavity, skin and breast: Reduced expression of lecithin:retinol acyltransferase in carcinoma lines. Carcinogenesis 2000, 21, 1925–1933. [CrossRef]
32. Altucci, L.; Rossin, A.; Hirsch, O.; Nebbioso, A.; Vitoux, D.; Wilhelm, E.; Guidez, F.; De Simone, M.; Schiavone, E.M.; Grimwade, D.; et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res. 2005, 65, 8754–8765. [CrossRef] [PubMed]

33. Sanchez, P.V.; Glantz, S.T.; Scotland, S.; Kasner, M.T.; Carroll, M. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors. Leukemia 2014, 28, 749–760. [CrossRef]

34. Germain, P.; Chambon, P.; Eichele, G.; Evans, R.M.; Lazar, M.A.; Leid, M.; De Lera, A.R.; Lotan, R.; Mangelsdorf, D.J.; Gronemeyer, H. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev. 2006, 58, 760–772. [CrossRef] [PubMed]

35. Alexander, S.P.; Cidlowski, J.A.; Kelly, E.; Marrion, N.V.; Peters, J.A.; Faccenda, E.; Harding, S.D.; Pawson, A.J.; Sharman, J.L.; Southan, C.; et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors. Br. J. Pharmacol. 2017, 174, S208–S224. [CrossRef]

36. Gronemeyer, H.; Gustafsson, J., M.P.; Cedenilla, M.; Ricote, M. Retinoid X receptors in macrophage biology. Trends Endocrinol. Metab. 2013, 24, 460–468. [CrossRef]

37. Roszer, T.; Menendez-Gutierrez, M.P.; Cedenilla, M.; Ricote, M. Retinoid X receptors in macrophage biology. Trends Endocrinol. Metab. 2013, 24, 460–468. [CrossRef]

42. Chen, J.D.; Evans, R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995, 377, 454–457. [CrossRef] [PubMed]

43. Heinzel, T.; Lavinsky, R.M.; Mullen, T.M.; Soderstrom, M.; Laherty, C.D.; Torchia, J.; Yang, W.M.; Brard, G.; Ngo, S.D.; Davie, J.R.; et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 1997, 387, 43–48. [CrossRef] [PubMed]

44. Nagy, L.; Kao, H.Y.; Love, J.D.; Li, C.; Banayo, E.; Gooch, J.T.; Krishna, V.; Chatterjee, K.; Evans, R.M.; Schwabe, J.W. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 1999, 13, 3209–3216. [CrossRef]

45. Bourguet, W.; Vivat, V.; Wurzt, J.M.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell. 2000, 5, 289–298. [CrossRef]

46. Glass, C.K.; Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000, 14, 121–141. [CrossRef]

47. Lonard, D.M.; O’Malley, B.W. Nuclear receptor coregulators: Judges, juries, and executioners of cellular regulation. Mol. Cell 2007, 27, 691–700. [CrossRef]

48. Perez, E.; Bourguet, W.; Gronemeyer, H.; de Lera, A.R. Modulation of RXR function through ligand design. Biochim. Biophys. Acta. 2012, 1821, 57–69. [CrossRef]

49. Niu, H.; Fujiwara, H.; di Martino, O.; Hadwiger, G.; Frederick, T.E.; Menendez-Gutierrez, M.P.; Ricote, M.; Bowman, G.R.; Welch, J.S. Endogenous retinoid X receptor ligands in mouse hematopoietic cells. Sci. Signal 2017, 10, eaan1011. [CrossRef]

50. Leblanc, B.P.; Stunnenberg, H.G. 9-Cis retinoic acid signaling: Changing partners causes some excitement. Genes Dev. 1995, 9, 1811–1816. [CrossRef]

51. Di Masi, A.; Leboffe, L.; De Marinis, E.; Pagano, F.; Cicconi, L.; Rochette-Egly, C.; Lo-Coco, F.; Ascenzi, P.; Nervi, C. Retinoic acid receptors: From molecular mechanisms to cancer therapy. Mol. Aspects Med. 2015, 41, 1–115. [CrossRef] [PubMed]
52. Niu, H.; Chacko, J.; Hadwiger, G.; Welch, J.S. Absence of natural intracellular retinoids in mouse bone marrow cells and implications for PML-RARA transformation. Blood Cancer J. 2015, 5, e284. [CrossRef] [PubMed]

53. Muenzner, M.; Tuvia, N.; Deutschmann, C.; Witte, N.; Tolkachov, A.; Valai, A.; Henze, A.; Sander, L.E.; RAIL, J.; SCHUPP, M. Retinol-Binding protein 4 and its membrane receptor STRA6 control adipogenesis by regulating cellular retinoid homeostasis and retinoic acid receptor alpha activity. Mol. Cell. Biol. 2013, 33, 4068–4082. [CrossRef] [PubMed]

54. Zhang, Y.; Creton, E.J.; Smith, T.E.S.; KOSHY, S.; Li, D.; Green, T.A. Manipulation of retinoic acid signaling in the nucleus accumbens shell alters rat emotional behavior. Behav. Brain Res. 2019, 376, 112177. [CrossRef]

55. ALTUCCI, L.; LEIBOWITZ, M.D.; Ogilvie, K.M.; de LERA, A.R.; Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 2007, 6, 793–810. [CrossRef]

56. Idres, N.; Marill, J.; Flexor, M.A.; Chabot, G.G. Activation of retinoic acid receptor-dependent transcription by all-retinoic acid metabolites and isomers. J. Biol. Chem. 2002, 277, 31491–31498. [CrossRef]

57. De Urquiza, A.M.; Liu, S.; Sjoberg, M.; Sjovall, J.; PERLMANN, T. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000, 290, 2140–2144. [CrossRef]

58. Lengqvist, J.; Mata De Urquiza, A.; Bergman, A.C.; Willson, T.M.; Sjovall, J.; Perlmann, T.; Griffiths, W.J. Polyunsaturated fatty acids including docosahexaenoic acid and arachidonic acid bind to the retinoid X receptor alpha-binding domain. Mol. Cell. Proteom. 2004, 3, 692–703. [CrossRef]

59. Carman, J.A.; Pond, L.; Nashold, F.; Wassom, D.L.; Hayes, C.E. Immunity to Trichinella spiralis infection in vitamin A-deficient mice. J. Exp. Med. 1992, 175, 111–120. [CrossRef]

60. Van Bennennum, A.M.; WONG YEN KONG, L.R.; Gijbels, M.J.; Tielen, F.J.; Roholl, P.J.; Brouwer, A.; Hendriks, H.F. Mitogen response of B cells, but not T cells, is impaired in adult vitamin A-deficient rats. J. Nutr. 1991, 121, 1960–1968. [CrossRef]

61. Canete, A.; Cano, E.; Munoz-Chapuli, R.; Carmona, R. Role of Vitamin A/Retinoic Acid in Regulation of Embryonic and Adult Hematopoiesis. Nutrients 2017, 9, 159. [CrossRef] [PubMed]

62. Ross, A.C.; CHEN, Q.; Ma, Y. Vitamin A and retinoic acid in the regulation of B-cell development and antibody production. Vitam. Horm. 2011, 86, 103–126. [CrossRef] [PubMed]

63. Ertesvag, A.; NADERI, S.; Blomhoff, H.K. Regulation of B cell proliferation and differentiation by retinoic acid. Semin. Immunol. 2009, 21, 36–41. [CrossRef] [PubMed]

64. Dolle, P. Developmental expression of retinoic acid receptors (RARs). Nucl. Recept. Signal. 2009, 7, e006. [CrossRef] [PubMed]

65. Duong, V.; Rochette-Egly, C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim. Biophys. Acta 2011, 1812, 1023–1031. [CrossRef]

66. Menendez-Gutierrez, M.P.; ROSZER, T.; Fuertes, L.; Nunez, V.; Escolano, A.; REDONDO, J.M.; De Clerck, N.; METZGER, D.; Valledor, A.F.; RICOTE, M. Retinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling. J. Clin. Investig. 2015, 125, 809–823. [CrossRef]

67. Ricote, M.; SNYDER, C.S.; LEUNG, H.Y.; Chen, J.; CHEN, K.R.; Glass, C.K. Normal hematopoiesis after conditional targeting of RXalpha in murine hematopoietic stem/progenitor cells. J. Leukoc. Biol. 2006, 80, 850–861. [CrossRef]

68. Szanto, A.; Narkar, V.; Shen, Q.; Uray, I.P.; Davies, P.J.; Nagy, L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ. 2004, 11 Suppl. 2, S126–S143. [CrossRef]

69. Kuppumbatti, Y.S.; BLEIWEISS, I.J.; Mandeli, J.P.; Waxman, S.; Mira, Y.L.R. Cellular retinol-binding protein expression and breast cancer. J. Natl. Cancer Inst. 2000, 92, 475–480. [CrossRef]

70. Osanai, M.; Lee, G.H. Enhanced expression of retinoic acid-metabolizing enzyme CYP26A1 in sunlight-damaged human skin. Med. Mol. Morphol. 2011, 44, 200–206. [CrossRef]

71. Osanai, M.; SAWADA, N.; Lee, G.H. Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1. Oncogene 2010, 29, 1135–1144. [CrossRef] [PubMed]

72. Jiang, F.; Qiu, Q.; Khanna, A.; Todd, N.W.; Deepak, J.; Xing, L.; Wang, H.; Liu, Z.; Su, Y.; Stass, S.A.; et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 2009, 7, 330–338. [CrossRef] [PubMed]
73. Kim, H.; Lapointe, J.; Kaygusuz, G.; Ong, D.E.; Li, C.; van de Rijn, M.; Brooks, J.D.; Pollack, J.R. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. *Cancer Res.* 2005, 65, 8118–8124. [CrossRef] [PubMed]

74. Sirchia, S.M.; Ferguson, A.T.; Sironi, E.; Subramanyan, S.; Orlandi, R.; Sukumar, S.; Sacchi, N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. *Oncogene* 2000, 19, 1556–1563. [CrossRef] [PubMed]

75. Campbell, M.J.; Park, S.; Uskokovic, M.R.; Dawson, M.J.; Koeflter, H.P. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog. *Endocrinology* 1998, 139, 1972–1980. [CrossRef] [PubMed]

76. Liu, X.; Nugoli, M.; Laferriere, J.; Saleh, S.M.; Rodrigue-Gervais, I.G.; Saleh, M.; Park, M.; Hallett, M.T.; Muller, W.J.; Giguerre, V. Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. *Proc. Natl. Acad. Sci. USA* 2011, 108, 774–779. [CrossRef] [PubMed]

77. Farinello, D.; Wozinska, M.; Lenti, E.; Genovese, L.; Bianchessi, S.; Migliori, E.; Sacchetti, N.; di Lillo, A.; Bertilacci, M.T.S.; de Lalla, C.; et al. A retinoic acid-dependent stroma-leukemia crossstalk promotes chronic lymphocytic leukemia progression. *Nat. Commun.* 2018, 9, 1787. [CrossRef]

78. Guo, G.; Sun, X.; Chen, C.; Wu, S.; Huang, P.; Li, Z.; Dean, M.; Huang, Y.; Jia, W.; Zhou, Q.; et al. Whole-Genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. *Nat. Genet.* 2013, 45, 1459–1463. [CrossRef]

79. Halstead, A.M.; Kapadia, C.D.; Bolzenius, J.; Chu, C.E.; Schriefer, A.; Wartman, L.D.; Bowman, G.R.; Arora, V.K. Bladder-Cancer-Associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. *Elife* 2017, 6. [CrossRef]

80. Wong, M.M.; Guo, C.; Zhang, J. Nuclear receptor corepressor complexes in cancer: Mechanism, function and regulation. *Am. J. Clin. Exp. Urol.* 2014, 2, 169–187.

81. Zhang, J.; Hug, B.A.; Huang, E.Y.; Chen, C.W.; Gelmetti, V.; Maccarana, M.; Minucci, S.; Pelicci, P.G.; Lazar, M.A. Oligomerization of ETO is obligatory for corepressor interaction. *Mol. Cell. Biol.* 2001, 21, 156–163. [CrossRef] [PubMed]

82. Gelmetti, V.; Zhang, J.; Fanelli, M.; Minucci, S.; Pelicci, P.G.; Lazar, M.A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. *Mol. Cell. Biol.* 1998, 18, 7185–7191. [CrossRef] [PubMed]

83. Koutsogiannouli, E.A.; Wagner, N.; Hader, C.; Pinkerneil, M.; Hoffmann, M.J.; Schulz, W.A. Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells. *Int. J. Mol. Sci.* 2017, 18, 1449. [CrossRef] [PubMed]

84. Zhang, C.; Zhong, J.F.; Stucky, A.; Chen, X.L.; Press, M.F.; Zhang, X. Histone acetylation: Novel target for the treatment of acute lymphoblastic leukemia. *Clin. Epigenet.* 2015, 7, 117. [CrossRef] [PubMed]

85. Lubbert, M.; Suciø, S.; Baira, L.; Ruter, B.H.; Platzbecker, U.; Giagounidis, A.; Selleslag, D.; Labar, B.; Germing, U.; Salih, H.R.; et al. Low-Dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. *J. Clin. Oncol.* 2011, 29, 1987–1996. [CrossRef] [PubMed]

86. Blagitko-Dorfs, N.; Schlosser, P.; Greve, G.; Pfeifer, D.; Meier, R.; Baude, A.; Brocks, D.; Plass, C.; Lubbert, M. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: Predominant synergistic gene downregulation associated with gene body demethylation. *Leukemia* 2019, 33, 945–956. [CrossRef]

87. Uy, G.L.; Lane, A.A.; Welch, J.S.; Grieselhuber, N.R.; Payton, J.E.; Ley, T.J. A protease-resistant PML-RAR[alpha] has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. *Blood* 2010, 116, 3604–3610. [CrossRef]

88. Merghoub, T.; Currieri, C.; Piazza, F.; Pandolfi, P.P. Modeling acute promyelocytic leukemia in the mouse: New insights in the pathogenesis of human leukemias. *Blood Cells Mol. Dis.* 2001, 27, 231–248. [CrossRef]

89. Miller, C.A.; Tricarico, C.; Skidmore, Z.L.; Uy, G.L.; Lee, Y.S.; Hassan, A.; O’Laughlin, M.D.; Schmidt, H.; Tian, L.; Duncavage, E.J.; et al. A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion. *Blood Adv.* 2018, 2, 1295–1299. [CrossRef]
90. Borrow, J.; Goddard, A.D.; Gibbons, B.; Katz, F.; Swirsky, D.; Fioretos, T.; Dube, I.; Winfield, D.A.; Kingston, J.; Hagemeijer, A.; et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: Detection of PML-RARA and RARA-PML fusion transcripts. *Br J. Haematol.* 1992, 82, 529–540. [CrossRef]
91. Juruc, J.G.; Soignet, S.L.; Maslak, A.P. Diagnosis and treatment of acute promyelocytic leukemia. *Curr. Oncol. Rep.* 2007, 9, 337–344. [CrossRef] [PubMed]
92. Segalla, S.; Rinaldi, L.; Kilsstrup-Nielsen, C.; Badaracco, G.; Minucci, S.; Pelicci, P.G.; Landsberger, N. Retinoic acid receptor alpha fusion to PML affects its transcriptional and chromatin-remodeling properties. *Mol. Cell. Biol.* 2003, 23, 8795–8806. [CrossRef] [PubMed]
93. Shen, Z.X.; Shi, Z.Z.; Fang, J.; Gu, B.W.; Li, J.M.; Zhu, Y.M.; Shi, J.Y.; Zheng, P.Z.; Yan, H.; Liu, Y.F.; et al. Characterization of atypical acute promyelocytic leukaemia: Three cases report. *Leukemia* 2019, 13, 1361–1371. [CrossRef]
94. Grignani, F.; De Matteis, S.; Nervi, C.; Tomassoni, L.; Gelmetti, V.; Fanelli, M.; Ruthardt, M.; Ferrara, F.F.; Zamir, I.; et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. *Nature* 1998, 391, 815–818. [CrossRef]
95. Lallemand-Breitenbach, V.; Zhu, J.; Puvion, F.; Koken, M.; Honore, N.; Doubleikovsky, A.; Duprez, E.; Pandolfi, P.P.; Puvion, E.; Freemont, P.; et al. Role of promyelocytic leukaemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. *J. Exp. Med.* 1991, 193, 1361–1371. [CrossRef]
96. Ding, W.; Li, Y.P.; Nobile, L.M.; Grills, G.; Carrera, I.; Paitena, E.; Tallman, M.S.; Wiernik, P.H.; Gallagher, R.E. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukaemia from treatment with all-trans retinoic acid and intensive chemotherapy. *Blood* 1998, 92, 1172–1183. [CrossRef]
97. Tobita, T.; Takeshita, A.; Kitamura, K.; Ohnishi, K.; Yanagi, M.; Hiraoka, A.; Karasuno, T.; Takeuchi, M.; Miyawaki, S.; Ueda, R.; et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. *Blood* 1997, 90, 967–973. [CrossRef]
98. Tomita, A.; Kiyoi, H.; Naoe, T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukaemia. *Int. J. Hematol.* 2013, 97, 717–725. [CrossRef]
99. Wang, X.; Wang, J.; Zhang, L. Characterization of atypical acute promyelocytic leukaemia: Three cases report and literature review. *Medicine* 2019, 98, e15537. [CrossRef]
100. Kitamura, K.; Kiyoi, H.; Yoshida, H.; Tobita, T.; Takeshita, A.; Ohno, R.; Naoe, T. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukaemia: Clinical and basic studies for the next generation. *Cancer Chemother. Pharmacol.* 2017, 40, S36–S41. [CrossRef]
101. Takeshita, A.; Asou, N.; Atsuta, Y.; Sakura, T.; Ueda, Y.; Sawa, M.; Dobashi, N.; Taniguchi, Y.; Suzuki, R.; Nakagawa, M.; et al. Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukaemia: A final result of prospective, randomized, JALSG-APL204 study. *Leukemia* 2019, 33, 358–370. [CrossRef] [PubMed]
102. Glasow, A.; Barrett, A.; Petrie, K.; Gupta, R.; Boix-Chornet, M.; Zhou, D.C.; Grimwade, D.; Gallagher, R.; von Lindern, M.; Waxman, S.; et al. DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. *Blood* 2008, 111, 2374–2377. [CrossRef] [PubMed]
103. Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstone, J.R.; Cole, P.A.; Casero, R.A.; Shi, Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* 2004, 119, 941–953. [CrossRef] [PubMed]
104. Schenk, T.; Chen, W.C.; Gollner, S.; Howell, L.; Jin, L.; Hebestreit, K.; Klein, H.U.; Popescu, A.C.; Burnett, A.; Mills, K.; et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. *Nat. Med.* 2012, 18, 605–611. [CrossRef] [PubMed]
105. McKeown, M.R.; Corces, M.R.; Eaton, M.L.; Fiore, C.; Lee, E.; Lopez, J.T.; Chen, M.W.; Smith, D.; Chan, S.M.; Koenig, J.L.; et al. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARalpha Dependency Targetable by SY-1425, a Potent and Selective RARalpha Agonist. *Cancer Discov.* 2017, 7, 1136–1153. [CrossRef] [PubMed]
106. El Hajj, H.; Dassouki, Z.; Berthier, C.; Raffoux, E.; Ades, L.; Legrand, O.; Hleihel, R.; Sahin, U.; Tawil, N.; Salemeh, A.; et al. Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. *Blood* 2015, 125, 3447–3454. [CrossRef] [PubMed]
107. Lugthart, S.; van Drunen, E.; van Norden, Y.; van Hoven, A.; Erpelinck, C.A.; Valk, P.J.; Beverloo, H.B.; Lowenberg, B.; Delwel, R. High EVI1 levels predict adverse outcome in acute myeloid leukemia: Prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008, 111, 4329–4337. [CrossRef]

108. Buteyn, N.J.; Fatechand, K.; Santhanam, R.; Fang, H.; Dettorre, G.M.; Gautam, S.; Harrington, B.K.; Henderson, S.E.; Merchand-Reyes, G.; Mo, X.; et al. Anti-Leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int. Immunol. 2018, 30, 375–383. [CrossRef]

109. White, E. The role for autophagy in cancer. J. Clin. Investig. 2015, 125, 42–46. [CrossRef]

110. Rothe, K.; Porter, V.; Jiang, X. Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions. Int. J. Mol. Sci. 2019, 20, 461. [CrossRef]

111. Moosavi, M.A.; Djavaheri-Mergny, M. Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia. Int. J. Mol. Sci. 2019, 20, 3559. [CrossRef] [PubMed]

112. Orfali, N.; O’Donovan, T.R.; Nyhan, M.J.; Britschgi, A.; Tschan, M.P.; Cahill, M.R.; Mongan, N.P.; Gudas, L.J.; McKenna, S.L. Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation. Exp. Hematol. 2015, 43, 781–793.e2. [CrossRef] [PubMed]

113. Shen, D.; Yu, X.; Wu, Y.; Chen, Y.; Li, G.; Cheng, F.; Xia, L. Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers. Expert Rev. Anticancer Ther. 2018, 18, 487–499. [CrossRef] [PubMed]

114. Desvergne, B. RXR: From partnership to leadership in metabolic regulations. Vitam. Horm. 2007, 75, 1–32. [CrossRef]

115. Tsai, D.E.; Luger, S.M.; Andreadis, C.; Vogl, D.T.; Kemner, A.; Potuzak, M.; Goradia, A.; Loren, A.W.; Perl, A.E.; Schuster, S.J.; et al. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin. Cancer Res. 2008, 14, 5619–5625. [CrossRef]

116. Welch, J.S.; Niu, H.; Uy, G.L.; Westervelt, P.; Abboud, C.N.; Vij, R.; Stockerl-Goldstein, K.E.; Jacoby, M.; Pusic, I.; Schroeder, M.A.; et al. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Am. J. Hematol. 2014, 89, E103–E108. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).